Mineralys Therapeutics presents positive results from Phase 3 trial for hypertension treatment.

From GlobeNewswire: 2025-05-24 04:30:00

Mineralys Therapeutics announced detailed results from the Phase 3 Launch-HTN trial, demonstrating lorundrostat’s efficacy in over 1,000 participants with uncontrolled or resistant hypertension. Lorundrostat 50 mg showed significant reductions in systolic blood pressure at Week 6 and Week 12, with favorable safety and tolerability profiles. Results were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection. Dysregulated aldosterone levels are a key driver of hypertension, affecting 30% of patients. Lorundrostat, a highly selective aldosterone synthase inhibitor, has shown promise in reducing blood pressure in hypertensive patients.

Safety results from the Launch-HTN trial showed lorundrostat’s favorable safety and tolerability profile, with modest and reversible effects on serum electrolytes. Treatment-emergent serious adverse events were low, with hyperkalemia incidences at 1.1% and 1.5% in different arms. Results from the Advance-HTN trial have been published, showing lorundrostat’s potential as a treatment for hypertension. Less than 50% of hypertension patients achieve their blood pressure goals with current medications, highlighting the need for new targeted treatments like lorundrostat.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease, and obstructive sleep apnea. Lorundrostat, their lead product candidate, is an orally administered aldosterone synthase inhibitor showing promising results in reducing blood pressure in hypertensive patients. The company is dedicated to addressing the unmet needs of patients with dysregulated aldosterone levels, a key factor in hypertension.



Read more at GlobeNewswire: Mineralys Therapeutics Announces Late-Breaking Presentation